About Us

Alan Schneyer, Ph.D., CEO and Chief Scientific Officer (Co-founder)

Alan Schneyer, CEO of Fairbanks PharmaceuticalsFollowing his undergraduate degree from the University of Pennsylvania and his doctoral degree from the University of Miami, Dr. Schneyer was awarded an NIH Postdoctoral Fellowship at Albany Medical College where he was trained in biochemical endocrinology. In 1987 he was recruited to the Massachusetts General Hospital where he ran an NIH-funded laboratory for 20 years.  In 2007, he moved to the Pioneer Valley Life Science Institute to pursue his discovery that the protein Follistatin Like-3 (FSTL3) was involved with regulating insulin-producing pancreatic beta cells.  In 2012, he joined the faculty of the Veterinary and Animal Science Department at University of Massachusetts-Amherst where he remains.  Over the years, funding for this work has been provided by the National Institutes of Health and the Juvenile Diabetes Research Foundation.  Dr. Schneyer is the Co-founder of Fairbanks Pharmaceuticals and directs all research programs.

Elissa Brown, MS, Chief Operating Officer (Co-founder)

Ms Brown is Co-founder of Fairbanks Pharmaceuticals.  She has been involved with business development and consulting for over 30 years and provides long-range planning for the Company.  Ms. Brown has an undergraduate degree from Hamilton College and a master’s degree from Northwestern University.

Alyssa Berthelette, Technician

Alyssa completed her Bachelors of Arts Degree with academic honors in Biology  at Assumption College in Worcester where she gained experience with modern laboratory technology. Additional experience was obtained through an internship at Genzyme (a Sanofi Company) in Framingham. Alyssa was offered a permanent position with Fairbanks after successfully completing a Massachusetts Life Science Center funded internship.

Melissa Brown, PhD, Consultant on Islet Studies

Dr. Brown, Professor at the University of New Haven, has completed training and research programs in human and animal islet transplantation. She began collaborating with Dr. Schneyer in 2008 when she formed the islet biology laboratory focused on analysis of FSTL3 and follistatin mutant mice in collaboration with Dr. Schneyer’s NIH funded program. She also analyzed human islets from normal and diabetic donors to discover that activin could restore glucose responsive insulin release to non-functional diabetic islets. Dr. Brown will provide islet isolation and analysis services to Fairbanks Pharmaceuticals during this Phase 1 project as needed.